Patent classifications
G01N2333/3156
Method of diagnosing pneumonia by detecting a volatile organic compound
The present invention relates to a method of diagnosing an existing or developing acute pneumonia induced by a microorganism by detecting one or more volatile organic compound(s) in a subject's sample and the use of one or more volatile organic compound(s) for the detection of Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae or Haemophilus influenza and optionally opportunistic pathogen Candida albicans.
Assay for Diagnosing Streptococcus Pneumoniae
Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The assays may also be used in combination with assays that detect streptococcal nucleic acids.
Devices and assays for diagnosis of sinusitis
Methods and kits for sampling mucous from within a sinus to determine if a single sample includes one or more bacterial types indicating bacterial sinusitis.
Assay for diagnosing Streptococcus pneumoniae
Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The assays may also be used in combination with assays that detect streptococcal nucleic acids.
Human <i>Streptococcus pneumoniae </i>antibodies and uses therefor
The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.